clinical trial · NCT06450275
Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets
Humanis Saglık Anonim Sirketi·phase1·completed·n = 32
HIV InfectionsDolutegravir 50 MG Film Coated TabletTivicay 50mg, film-coated tablets
brief summary
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Dolutegravir 50mg film-coated tablets (50mg Dolutegravir) versus Tivicay 50mg film-coated tablets (50mg Dolutegravir) in healthy subjects under fasting conditions.
started
Jan 3, 2024
primary completion
Jan 15, 2024
completion
Mar 7, 2024
last updated
Jun 10, 2024
official title
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets (50mg Dolutegravir) Versus Tivicay 50mg Film-coated Tablets (50mg Dolutegravir) in Healthy Subjects Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol